Dynavax to Present at the 7th Annual JMP Securities Healthcare Conference
BERKELEY, CA, Jul 09, 2012 (MARKETWIRE via COMTEX) -- Dynavax Technologies
Corporation (DVAX) announced today that it plans to present at the 7th Annual JMP
Securities Healthcare Conference in New York on Thursday, July 12, at 10:00 a.m.
EDT (7:00 a.m. PDT).
Tyler Martin, M.D., President and Chief Medical Officer of Dynavax, will provide
a company overview. To access the slide presentation, live webcast, and
subsequent archived recording, please visit Dynavax's website at
investors.dynavax.com.
About Dynavax Dynavax Technologies Corporation, a clinical-stage
biopharmaceutical company, discovers and develops novel products to prevent and
treat infectious and inflammatory diseases. The Company's lead product candidate
is HEPLISAV(TM), a Phase 3 investigational adult hepatitis B vaccine designed to
provide higher and earlier protection with fewer doses than currently licensed
vaccines. A U.S. BLA for HEPLISAV has been accepted for review by the FDA. For
more information visit dynavax.com. |
